Long noncoding RNA DNAJC3-AS1 (lncRNA DNAJC3-AS1) has been probed in many studies, while the regulatory mechanism of DNAJC3-AS1 on papillary thyroid carcinoma (PTC) via regulating microRNA (miR)-27a-3p remains inadequate. This research aims to depict the role of DNAJC3-AS1, miR-27a-3p, collagen, and calcium-binding EGF domain-containing protein 1 (CCBE1) on PTC development. DNAJC3-AS1, miR-27a-3p, and CCBE1 expression levels in PTC tissues and adjacent normal tissues were tested. The relation of DNAJC3-AS1, miR-27a-3p, and CCBE1 was analyzed. DNAJC3-AS1 and miR-27a-3p and CCBE1-related oligonucleotides were transfected into IHH-4 cells to investigate their role in PTC development. Cell tumorigenicity was detected by in vivo assay. DNAJC3-AS1 and CCBE1 expressed highly and miR-27a-3p expressed lowly in PTC. Downregulation of DNAJC3-AS1, upregulating miR-27a-3p or downregulating CCBE1 impaired the malignant behaviors of IHH-4 cells. Depletion of miR-27a-3p reversed the DNAJC3-AS1 suppression-induced phenotypic inhibition of IHH-4 cells. DNAJC3-AS1 bound to miR-27a-3p and CCBE1 as a target of miR-27a-3p. Our study highlights that DNAJC3-AS1 inhibits miR-27a-3p to promote CCBE1 expression, thereby facilitating PTC development. This study affords distinguished therapeutic strategies and novel research directions for PTC treatment.

and "breast carcinoma" and the individual corresponding free terms. The search was performed in October 2019 and restricted to English language. Furthermore, we checked manually the reference lists of relevant studies to ensure that no studies were lost. Selection criteriaSelected studies must meet the following inclusion criteria: (1) The case group was a woman with BC, and the control group was a healthy woman without thyroid disease or breast disease. (2) Studies must include serum levels of FT 3 and FT 4 hormones. (3) Quantification of FT 3 and FT 4 was performed by thyroid function test. (4) The design was quantitative (mean and standard deviation).(5) Any studies failing to meet the above criterion were excluded from the meta-analysis. Data extractionThe data were extracted by two independent investigators (L.Z.W. and Z.B.) and the coincidence rate was 95.3%. Subsequently the data were validated by other investigators. The quality of the studies was evaluated using the Agency for Healthcare Research and Quality (AHRQ) and the Newcastle-Ottawa Scale (NOS) by two investigators (GD and DQ). Data collection included the following information: author information, publication date, study type, country, number of cases and controls, and selected indexes (mean ± SD). If the information was missing and the unit was not unified, we contacted the author and unified the unit (FT3: pmol/L, FT4: ng/dL). Table 1 shows the data general situation of each study included in this study.We searched the PubMed, EMBASE, Cochrane Library, and Google Scholar databases using the medical subject heading keywords "Hy-